Aller au contenu principal
Accès ouvert déclaré 2025 article

Adherence to Quality-of-Care Indicators and Mortality Outcomes in Patients With MRSA Bacteremia: A Post Hoc Analysis of the CAMERA2 Randomized Clinical Trial.

0Citations signalées, ce qui n’est pas une note de qualité
36Institutions déclarées
4Pays d’affiliation déclarés

Rattachement africain : sg, au, nz, il. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Importance: Adherence to quality-of-care indictors (QCIs) is associated with better Staphylococcus aureus bacteremia (SAB) outcomes. It is unknown whether clinical trial participation adventitiously improves QCI adherence and clinical outcomes compared with nontrial routine care for SAB. Objective: To evaluate whether health care practitioners of trial participants with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia have better QCI adherence compared with practitioners of contemporaneous nontrial patients with MRSA bacteremia and whether QCI adherence or trial participation is associated with lower mortality. Design, Setting, and Participants: This ad hoc, post hoc analysis of the Combination Antibiotics for Methicillin-Resistant Staphylococcus aureus (CAMERA2) Trial included 17 CAMERA2 hospital sites from 4 countries. The present study involved data collection mirroring the CAMERA2 case report forms from nontrial patients selected from sites' CAMERA2 screening logs. The newly collected data were analyzed with existing data from trial participants. Both groups of patients were diagnosed with MRSA bacteremia between August 2015 and July 2018. Statistical analyses were performed from September 2024 to February 2025. Exposures: Nontrial vs trial participation, including health care practitioner adherence to 7 evidence-based QCIs (individually and collectively) for SAB management. Main Outcome and Measures: All-cause 90-day mortality; the association of the exposures with this outcome was assessed using Cox proportional hazards regressions. Multiple sensitivity analyses were performed, including propensity score matching and exclusion of early deaths. Results: This study included 722 participants (467 nontrial [64.7%] and 255 trial [35.3%]; mean [SD] age, 63.2 [18.4] years; 482 [66.8%] male). Demographics were comparable in the 2 study groups. Nontrial patients had a higher range of Charlson Comorbidity Index (median, 2.0 [range, 0-16.0] vs 2.0 [range, 0-13.0]; P < .001) and Pitt bacteremia score (median, 1.0 [range, 1.0-12.0] vs 1.0 [range, 1.0-7.0]; P < .001) compared with trial participants. Ninety-day mortality was not significantly different in the nontrial and trial groups (106 of 457 [23.2%] vs 48 of 251 [19.1%]; P = .25). Health care practitioners of nontrial patients had a lower mean (SD) number of adherent QCIs compared with practitioners of trial participants (3.90 [1.38] vs 4.28 [1.17]; P = .003). While increasing number of adherent QCIs was associated with lower 90-day mortality (adjusted hazard ratio [AHR], 0.73; 95% CI, 0.59-0.91; P = .005), adherence to QCIs individually was not associated with lower mortality. Study group (nontrial vs trial) was not associated with mortality (AHR, 1.08; 95% CI, 0.73-1.61; P = .68). Conclusions and Relevance: In this post hoc analysis of a randomized clinical trial, health care practitioners of trial participants had greater adherence to QCIs for MRSA bacteremia management compared with practitioners of nontrial patients. Trial participation was not associated with lower mortality.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Adherence to Quality-of-Care Indicators and Mortality Outcomes in Patients With MRSA Bacteremia
Date Crossref
25/07/2025
Éditeur
American Medical Association (AMA)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Agency for Science pays non établi dans la notice
    Organisme public
  • National Environment Agency pays non établi dans la notice
    Organisme public
  • National Centre for Infectious Diseases pays non établi dans la notice
    Établissement de santé
  • Communicable Diseases Agency pays non établi dans la notice
    Organisme public
  • Singapore Clinical Research Institute pays non établi dans la notice
    Institution
  • The University of Sydney Westmead Hospital pays non établi dans la notice
    Université ou école supérieure
  • Westmead Hospital New South Wales Health Pathology pays non établi dans la notice
    Établissement de santé
  • NSW Health Pathology pays non établi dans la notice
    Établissement de santé
  • Blacktown & Mount Druitt Hospital pays non établi dans la notice
    Établissement de santé
  • Murdoch University pays non établi dans la notice
    Université ou école supérieure
  • Royal Perth Hospital pays non établi dans la notice
    Établissement de santé
  • Fiona Stanley Hospital pays non établi dans la notice
    Établissement de santé

Agency for Science, National Environment Agency et National Centre for Infectious Diseases, avec 9 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Antimicrobial Resistance in StaphylococcusAntibiotic Use and ResistanceMedication Adherence and Compliance

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.